Breaking News Instant updates and real-time market news.

JPM

JPMorgan

$111.83

0.99 (0.89%)

, WFC

Wells Fargo

$62.85

-0.165 (-0.26%)

12:25
01/12/18
01/12
12:25
01/12/18
12:25

On The Fly: Top stock stories at midday

Stocks opened mixed, with the Dow and S&P higher and the Nasdaq struggling under the weight of Facebook (FB). The Dow and S&P continued to tack on big gains and the Nasdaq resumed its climb shortly after the open. Each of the major averages is now higher by at least 0.5% with the Dow now closing in on 25,800. Oil prices began the day lower but have recouped their losses and are now little changed for the day. ECONOMIC EVENTS: In the U.S., the consumer price index came in firmer for December, with the "core" rise of 0.3% topping the consensus forecast for a 0.2% monthly gain and the "headline" CPI in-line with expectations with a 0.1% monthly advance. December retail sales increased 0.4% for both the broader control group and the group excluding autos and gas, which was roughly in-line with expectations. Business inventories grew 0.4% in November, as expected. COMPANY NEWS: Shares of JPMorgan (JPM) advanced 1% after the bank reported better than expected adjusted earnings and managed revenue in the fourth quarter. CEO Jamie Dimon said the enactment of tax reform is a "significant positive outcome for the country" and as a result of the tax plan the bank will be "increasing and accelerating" some of its investments in "employees, customers and communities" it serves. Well Fargo (WFC) also reported better than expected earnings but its revenue fell a bit short to the consensus forecast. Its shares are flat near noon following the report... Facebook (FB) shares have dropped 4% after CEO Mark Zuckerberg posted an announcement to his Facebook profile which explained that he is directing his product teams to change the way that they build Facebook to focus more on "meaningful social interactions" rather than relevant content. Stifel analyst Scott Devitt downgraded the stock to Hold from Buy afterward, arguing there is currently "too much uncertainty" relating to the economic impact of the company's pending News Feed changes communicated by Zuckerberg. Several other analysts, however, have been defending the stock, with Piper Jaffray analyst Sam Kemp saying he doubts the changes will have a material impact on revenue and KeyBanc analyst Andy Hargreaves among those recommending buying the shares amid the selloff. MAJOR MOVERS: Among the notable gainers was Astronics (ATRO), which rose 17% after the company guided for fiscal 2018 revenue above consensus estimates. Also higher was Kohl's (KSS), which gained 4% after the stock was upgraded to Sector Perform at RBC Capital and to Overweight at JPMorgan. Among the noteworthy losers was Concert Pharmaceuticals (CNCE), which dropped 26% after the USPTO denied the company's request for a Post Grant Review on Incyte's (INCY) '335 patent for Jakafi. Also lower was GameStop (GME), which slid 10% after the game retailer reported on its holiday sales and said it now sees FY17 EPS near the middle of its prior guidance range. INDEXES: Near midday, the Dow was up 201.21, or 0.79%, to 25,775.94, the Nasdaq was up 39.37, or 0.55%, to 7,251.15, and the S&P 500 was up 15.28, or 0.55%, to 2,782.84.

JPM

JPMorgan

$111.83

0.99 (0.89%)

WFC

Wells Fargo

$62.85

-0.165 (-0.26%)

ATRO

Astronics

$40.97

0.75 (1.86%)

KSS

Kohl's

$63.45

2.33 (3.81%)

CNCE

Concert Pharmaceuticals

$27.68

-0.35 (-1.25%)

INCY

Incyte

$93.06

-3.56 (-3.68%)

GME

GameStop

$17.87

-2.09 (-10.47%)

  • 12

    Jan

  • 12

    Jan

  • 12

    Jan

  • 18

    Jan

  • 27

    Feb

  • 01

    Mar

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

JPM JPMorgan
$111.83

0.99 (0.89%)

12/21/17
BUCK
12/21/17
UPGRADE
Target $135
BUCK
Buy
JPMorgan upgraded to Buy on lower tax rate, share gains at Buckingham
As previously reported, Buckingham upgraded JPMorgan to Buy from Neutral and raised its price target to $135 from $100. Analyst James Mitchell raised estimates to reflect "sizable" earnings leverage from the lower tax rate and views increasing buybacks as a tailwind with potential regulatory reform accelerating capital returns. Mitchell views JPMorgan as having a best-in-class franchise with upside through market share gains on multiple fronts .
12/21/17
12/21/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Darden (DRI) upgraded to Buy from Hold at Argus with analyst John Staszak citing the company's "strong" second quarter report, contending that the company can transfer the initiatives to price aggressively, lower costs and increase customer traffic at Olive Garden to also improve results at its specialty brands. 2. Exxon Mobil (XOM) was upgraded to Focus List from Outperform and Royal Dutch Shell (RDS.A) was upgraded to Outperform at Scotia Howard Weil. 3. JPMorgan (JPM) and Wells Fargo (WFC) were upgraded to Buy from Neutral at Buckingham. 4. Community Bank System (CBU) upgraded to Hold from Sell at Sandler O'Neill. 5. Spirit Airlines (SAVE) upgraded to Buy from Hold at Deutsche Bank with analyst Michael Linenberg saying he believes Airline underperformers in 2017 could see the most upside in 2018 as their prospects improve. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/21/17
BUCK
12/21/17
UPGRADE
BUCK
Buy
JPMorgan upgraded to Buy from Neutral at Buckingham
01/09/18
SOCG
01/09/18
DOWNGRADE
Target $120.5
SOCG
Hold
JPMorgan downgraded to Hold from Buy at Societe Generale
Societe Generale analyst Andrew Lim downgraded JPMorgan to Hold saying the stock is now fairly priced following the recent rally. The analyst raised his price target for the shares to $120.50 from $113.
WFC Wells Fargo
$62.85

-0.165 (-0.26%)

01/10/18
ATLE
01/10/18
UPGRADE
Target $64
ATLE
Neutral
Wells Fargo upgraded to Neutral at Atlantic Equities
As previously reported, Atlantic Equities analyst John Heagerty upgraded Wells Fargo (WFC) to Neutral from Underweight, as his analysis leads him to increase his FY18 EPS view by 11% on average for the banks he covers. He also sees positive secondary effects for the banks from higher U.S. GDP growth. Heagerty raised his price target on Wells Fargo shares to $64 from $55. The analyst also upgraded Morgan Stanley (MS) to Overweight this morning, citing the same analysis of the potential benefits from tax reform.
01/10/18
01/10/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) upgraded to Neutral from Underweight at Atlantic Equities by analyst John Heagerty, as his analysis leads him to increase his FY18 EPS view by 11% on average for the banks he covers. He also sees positive secondary effects for the banks from higher U.S. GDP growth. Heagerty raised his price target on Wells Fargo shares to $64 from $55. The analyst also upgraded Morgan Stanley (MS) to Overweight this morning, citing the same analysis of the potential benefits from tax reform. 2. Deere upgraded to Outperform from Sector Perform at RBC Capital by analyst Seth Weber, who said he is positive on the company's leadership position in North American farm machinery which is stabilizing and exposure to the earth moving equipment category. The analyst is also constructive on Deere's recent Wirten Group acquisition. 3. Target (TGT) upgraded to Positive from Neutral at Susquehanna. 4. State Street (STT) and BNY Mellon (BK) upgraded to Buy from Neutral at Citi, with analyst Keith Horowitz saying he thinks the trust banks are the best way to play the digital transformation to the cloud and finds the current valuation as attractive. 5. RBS (RBS) upgraded to Overweight from Equal Weight at Morgan Stanley. Analyst Alvaro Serrano also downgraded Barclays (BCS) and Lloyds Banking (LYG). This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
01/10/18
ATLE
01/10/18
UPGRADE
Target $61
ATLE
Overweight
Morgan Stanley upgraded on tax reform benefits at Atlantic Equities
As previously reported, Atlantic Equities analyst John Heagerty upgraded Morgan Stanley (MS) to Overweight from Neutral, as his analysis leads him to increase his FY18 EPS view by 11% on average for the banks he covers. He also sees positive secondary effects for the banks from higher U.S. GDP growth. Heagerty raised his price target on Morgan Stanley shares to $61 from $48. The analyst also upgraded Wells Fargo (WFC) to Neutral from Underweight this morning, citing the same analysis of the potential benefits from tax reform.
01/10/18
ATLE
01/10/18
UPGRADE
ATLE
Neutral
Wells Fargo upgraded to Neutral from Underweight at Atlantic Equities
ATRO Astronics
$40.97

0.75 (1.86%)

01/12/18
ADAM
01/12/18
NO CHANGE
Target $48
ADAM
Buy
Astronics revenue inflection not reflected yet in stock, says Canaccord
Canaccord analyst Ken Herbert noted Astronics announced an increase in 2018 revenue guidance with an increase in both its Aerospace and Test businesses. The analyst believes both should be a positive and he said estimates will move higher to reflect the likely tax benefits and will provide an additional tailwind. He does not believe the revenue inflection point has been fully reflected in the stock yet. Herbert reiterated his Buy rating and raised his price target to $48 from $46 on Astronics shares.
12/12/17
ADAM
12/12/17
NO CHANGE
Target $46
ADAM
Buy
Astronics price target raised to $46 from $40 at Canaccord
Canaccord analyst Ken Herbert adjusted Astronics estimates to reflect the recent closure of the Telefonix acquisition and believes the deal will add $10M in 2018 EBIT, or approximately 10c to earnings. The analyst raised Astronics' price target to $46 from $40 to reflect an improved 2018 outlook and reiterated his Buy rating on share.
10/09/17
RBCM
10/09/17
NO CHANGE
Target $209
RBCM
Outperform
Defense and Aerospace sector poised for strong Q3, says RBC Capital
RBC Capital analyst Matthew McConnell previewed the Q3 earnings season for the defense and commercial aviation industries, raising price targets across the sectors. In defense, McConnell likes the companies with focus on international markets, where demand has not yet been reflected in orders or backlog. Among his favorites, McConnell raises the price target on Raytheon (RTN) to $209 from $193, General Dynamics (GD) to $241 from $220, Northrop Grumman (NOC) to $324 from $294, Lockheed Martin (LMT) to $327 from $289, and Triumph (TGI) to $38 from $33. He also states that there may be room for some consolidation in defense given that budget up-cycle is only 2 years old, profiling Astronics (ATRO), Barnes (B), Esterline (ESL), Heico (HEI), and Textron (TXT) as some of the potential targets. In commercial aviation, McConnell sees Boeing (BA) upside driven by continued strong air traffic growth, mature sales campaigns, and expectations for a strong wide-body replacement cycle starting in the early 2020s, raising his price target on Boeing to $269 from $235.
10/05/17
ADAM
10/05/17
NO CHANGE
Target $36
ADAM
Buy
Canaccord says time to revisit Astronics
Canaccord analyst Ken Herbert believes it is time to revisit Astronics as the shares have significantly underperformed the Aerospace & Defense sector and have not seen any real bounce amid the improved sentiment around the commercial aerospace cycle. He believes the current price represents a good risk/reward as growth in the aerospace sector has reached an inflection point. Herbert maintained his Buy rating and raised his price target to $36 from $34 on Astronics shares.
KSS Kohl's
$63.45

2.33 (3.81%)

01/12/18
RBCM
01/12/18
UPGRADE
Target $60
RBCM
Sector Perform
Kohl's upgraded to Sector Perform at RBC Capital on improving comps
As reported earlier, RBC Capital analyst Brian Tunick upgraded Kohl's to Sector Perform from Underperform and raised his price target to $60 from $39. Tunick cites sequentially improving comps in 2017 that led to 7% SSS increase in the holiday period - "one of the strongest comps in retail" - along with the management's focus on store fleet optimization, cost management, and balance sheet control.
01/12/18
RBCM
01/12/18
UPGRADE
RBCM
Sector Perform
Kohl's upgraded to Sector Perform from Underperform at RBC Capital
01/12/18
BMOC
01/12/18
NO CHANGE
Target $60
BMOC
Market Perform
Kohl's price target raised to $60 from $43 at BMO Capital
BMO Capital analyst Wayne Hood raised his price target on Kohl's to $60 after the company's better than expected comps for November-December. Hood also noted the presentation from CEO Kevin Mansell at the ICR Conference that highlighted improving traffic and operations trends within the company's "Greatness Agenda" initiative launched in 2014 that was based on the pillars of "Easy Experience, Amazing Products, Personalized Connections, and Incredible Savings". The analyst keeps his Market Perform rating on Kohl's.
01/12/18
01/12/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dick's Sporting (DKS) upgraded to Buy from Hold at Deutsche Bank with analyst Mike Baker saying he believes industry trends are bottoming and notes that Dick's inventory levels are coming back into balance with demand, which should lessen the impact on gross margins. 2. eBay (EBAY) upgraded to Buy from Hold at SunTrust with analyst Youssef Squali citing an upbeat fourth quarter holiday sales boosting revenues and gross merchandise volume, prospects for higher growth in 2018 on platform improvements and marketing investment, lowers corporate tax rates, and lower repatriation tax rates that will bring "most of $8.7B" in overseas cash to be used in buybacks or M&A. 3. Costco (COST) upgraded to Buy from Accumulate at Gordon Haskett with analyst Chuck Grom citing his meeting with management. 4. Kohl's (KSS) was upgraded to Overweight from Neutral at JPMorgan and to Sector Perform from Underperform at RBC Capital. 5. Humana (HUM) and Anthem (ANTM) were upgraded to Buy from Hold at Jefferies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CNCE Concert Pharmaceuticals
$27.68

-0.35 (-1.25%)

01/12/18
STFL
01/12/18
NO CHANGE
Target $27
STFL
Buy
Concert pullback on PTAB decision a buying opportunity, says Stifel
Stifel analyst Adam Walsh called the news that the USPTO denied Concert Pharmaceuticals' Post Grant Review petition on Incyte's (INCY) '335 patent for Jakafi a "setback," but "certainly not the end" for Concert's deuterated ruxolitinib for alopecia areata. The PTAB decision does not prohibit Concert from challenging the '335 patent's validity at a later time in court, noted Walsh, who also points out the Phase 2a trial in alopecia areata will continue as planned. The analyst, who sees today's pullback as a buying opportunity, keeps a Buy rating on Concert shares but lowered his price target on the stock to $27 from $30.
01/12/18
MZHO
01/12/18
DOWNGRADE
MZHO
Neutral
Concert Pharmaceuticals downgraded to Neutral from Buy at Mizuho
01/12/18
01/12/18
DOWNGRADE
Target $23

Neutral
Concert Pharmaceuticals downgraded on valuation, litigation overhang at Mizuho
As previously reported, Mizuho analyst Difei Yang downgraded Concert Pharmaceuticals (CNCE) to Neutral from Buy, calling the stock fairly valued at current levels. Additionally, while Yang does not believe the Patent Trial and Appeal Board decision to deny a Post Grant Review in the company's ongoing dispute with Incyte (INCY) has any implications for the ultimate outcome of Concert's trial, the decision does leave a litigation overhang on the stock. Also, two phase 3 trial readouts for AVP-786 were pushed out to 2019, leaving Concert with one less potential catalyst in 2018, said Yang, who keeps a $23 price target on the stock.
12/19/17
UBSW
12/19/17
NO CHANGE
Target $34
UBSW
Buy
Concert Pharmaceuticals price target raised to $34 from $22 at UBS
UBS analyst Jeffrey Hung raised his price target on Concert Pharmaceuticals to $34 from $22 to reflect higher than expected demand for novel alopecia treatments. He continues to see a substantial opportunity for its alopecia treatment and increased his launch assumptions. The analyst also pointed to the company's clinical candidates that demonstrate the strategic value of the platform and pipeline optionality. Hung reiterated his Buy rating on Concert Pharmaceuticals shares.
INCY Incyte
$93.06

-3.56 (-3.68%)

01/08/18
STFL
01/08/18
NO CHANGE
STFL
Buy
NewLink Genetics timelines mostly in-line with prior guidance, says Stifel
Stifel analyst Stephen Willey noted that NewLink Genetics (NLNK) now expects to complete the majority of enrollment in the Indigo301 melanoma trial by year-end, versus its previous expectation to complete enrollment in 2018, which he said is likely due to additional time required for dose optimization of the novel indoximod salt formulation. The remainder of the 2018 calendar the company laid out is full of mostly expected catalysts and in-line with prior guidance, said Willey, who still expects NewLink to remain levered to Incyte's (INCY) date from the Phase 3 ECHO-301 trial. Willey keeps a Buy rating on NewLink shares.
01/08/18
DBAB
01/08/18
NO CHANGE
Target $110
DBAB
Buy
Celgene deal 'incremental negative' for Incyte, says Deutsche Bank
Deutsche Bank analyst Navin Jacob calls Celgene's (CELG) acquisition of Impact Biomedicines "one step" in the right direction. The analyst estimates Impact's Jak2 inhibitor fedratinib can achieve 20% of peak Jakafi sales in myelofibrosis and polycythemia vera, which translates to $1B. The asset fits Celgene's business and the $2.4B that the company is paying over the next two years "doesn't appear egregious for a commercial ready asset," Jacob tells investors in a research note. The analyst also views Celgene's acquisition as an "incremental negative" for Incyte (INCY). Given direct overlap, any future potential acquisition of Incyte by Celgene has been removed, Jacob contends. He keeps a Hold rating on Celgene with a $110 price target.
GME GameStop
$17.87

-2.09 (-10.47%)

01/10/18
BARD
01/10/18
NO CHANGE
Target $23
BARD
Outperform
GameStop holiday results expected to be inline, says Baird
Baird analyst Colin Sebastian said he expects GameStop to report inline holiday sales, seeing strength in top-selling software and hardware products that should offset a few weak performers. He noted his channel checks do not include the sale of collectibles, which is becoming a larger part of GameStop's business. Sebastian reiterated his Outperform rating and $23 price target but said he would be more constructive on GameStop shares below $20.
12/07/17
BARD
12/07/17
NO CHANGE
BARD
Data so far suggesting healthy holiday game sales, says Baird
Baird analyst Colin Sebastian noted that French game maker Ubisoft (UBSFY) raised its revenue and margin guidance for the December quarter, which he views as a slight positive for video game industry sales momentum this holiday season. Data also point to solid sales for both Sony's (SNE) PS4 and Nintendo's (NTDOY) Switch, which are a driver of software as well as a key catalyst for Gamestop (GME), Sebastian added. Other publicly traded companies in the video game space include Activision Blizzard (ATVI), Electronic Arts (EA), Take-Two (TTWO) and Microsoft (MSFT).
11/30/17
LOOP
11/30/17
NO CHANGE
Target $28
LOOP
Buy
GameStop rollout of Pokemon Centers makes "infinite sense", says Loop Capital
Loop Capital analyst Anthony Chukumba says GameStop decision to roll out Pokemon Centers at its GameStop and ThinkGeek stores adds to the company's larger collectibles initiative and "makes infinite sense" due to the popularity of the franchise. Chukumba keeps his Buy rating and $28 price target on GameStop, saying collectibles are a natural product extension for its business.
01/12/18
LOOP
01/12/18
NO CHANGE
Target $26
LOOP
Buy
GameStop price target lowered to $26 from $28 at Loop Capital
Loop Capital analyst Anthony Chukumba said he saw several encouraging signs in GameStop's report of better than expected 2017 holiday sales. He keeps a Buy rating on the stock, but trimmed his price target on GameStop shares to $26 from $28, noting that the company also said it now sees FY17 EPS near the middle of its prior guidance range.

TODAY'S FREE FLY STORIES

VIRT

Virtu Financial

$29.10

-0.7 (-2.35%)

05:03
05/23/18
05/23
05:03
05/23/18
05:03
Initiation
Virtu Financial initiated  »

Virtu Financial initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KRO

Kronos Worldwide

$24.77

-0.165 (-0.66%)

04:59
05/23/18
05/23
04:59
05/23/18
04:59
Upgrade
Kronos Worldwide rating change  »

Kronos Worldwide upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSW

DSW

$25.64

0.04 (0.16%)

, JWN

Nordstrom

$45.79

-0.05 (-0.11%)

04:56
05/23/18
05/23
04:56
05/23/18
04:56
Downgrade
DSW, Nordstrom rating change  »

DSW downgraded to Hold…

DSW

DSW

$25.64

0.04 (0.16%)

JWN

Nordstrom

$45.79

-0.05 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

PLAB

Photronics

$9.05

0.6 (7.10%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Photronics to hold an analyst and investor event »

Analyst and Investor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

TMO

Thermo Fisher

$217.88

1.2 (0.55%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Thermo Fisher to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 23

    May

CAFD

8point3 Energy

$12.19

(0.00%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
8point3 Energy to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

WST

West Pharmaceutical

$90.09

-0.04 (-0.04%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
West Pharmaceutical management to meet with Jefferies »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 19

    Jun

FMBI

First Midwest

$26.40

0.25 (0.96%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
First Midwest management to meet with Piper Jaffray »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

SRDX

Surmodics

$49.10

0.8 (1.66%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Surmodics management to meet with Barrington »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 19

    Jun

  • 20

    Jun

  • 25

    Jun

  • 26

    Jun

OTEX

OpenText

$34.21

0.11 (0.32%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
OpenText management to meet with Benchmark »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

04:55
05/23/18
05/23
04:55
05/23/18
04:55
General news
Breaking General news story  »

FOMC Minutes to be…

WD

Walker & Dunlop

$56.00

-0.1 (-0.18%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Walker & Dunlop management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

  • 31

    May

WWE

WWE

$56.88

-0.98 (-1.69%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
WWE management to meet with MKM Partners »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

BMCH

BMC Stock Holdings

$19.75

-0.7 (-3.42%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
BMC Stock Holdings management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

LOGI

Logitech

$40.86

0.15 (0.37%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Logitech management to meet with Citi »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

04:55
05/23/18
05/23
04:55
05/23/18
04:55
General news
Breaking General news story  »

Minneapolis Federal…

MTOR

Meritor

$21.94

-0.2 (-0.90%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Meritor management to meet with RBC Capital »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 13

    Jun

GGG

Graco

$46.70

-0.64 (-1.35%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Graco management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

SSRM

SSR Mining

$10.28

-0.02 (-0.19%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
SSR Mining management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

NVEE

NV5 Global

$60.05

-0.55 (-0.91%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
NV5 Global management to meet with Lake Street »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 09

    Jun

  • 12

    Jun

  • 13

    Jun

QTM

Quantum

$3.65

0.025 (0.69%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Quantum management to meet with Lake Street »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 29

    May

WERN

Werner

$38.30

-0.7 (-1.79%)

, USAK

USA Truck

$23.19

-3.3 (-12.46%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
Wolfe Research to hold a conference »

11th Annual Global…

WERN

Werner

$38.30

-0.7 (-1.79%)

USAK

USA Truck

$23.19

-3.3 (-12.46%)

LKQ

LKQ Corp.

$30.14

-0.62 (-2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 12

    Jun

  • 13

    Jun

  • 20

    Jun

AGS

PlayAGS

$22.83

-0.21 (-0.91%)

, BYD

Boyd Gaming

$36.45

-0.54 (-1.46%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
SunTrust to hold a bus tour »

Casino Bus tour travels…

AGS

PlayAGS

$22.83

-0.21 (-0.91%)

BYD

Boyd Gaming

$36.45

-0.54 (-1.46%)

CZR

Caesars

$12.65

-0.2 (-1.56%)

RRR

Red Rock Resorts

$34.09

-0.54 (-1.56%)

LGND

Ligand

$187.19

1.95 (1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

SFBS

ServisFirst

$43.67

-0.01 (-0.02%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
ServisFirst management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 24

    May

FR

First Industrial Realty

$31.64

0.09 (0.29%)

04:55
05/23/18
05/23
04:55
05/23/18
04:55
Conference/Events
First Industrial Realty management to meet with SunTrust »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.